California Subpoenas OpenAI Files. Google Restricts Gemini Access. OpenAI Adds Invisible Watermark. Utah Launches AI Acne Prescriptions.

Show notes

The AI news for October 6th, 2026

--- This episode is sponsored by ---

Rocket Routine GmbH
Find our more about our today's sponsor Rocket Routine at
California compels OpenAI to disclose Hugging Face records.
Source: https://www.heise.de/news/Kalifornien-zwingt-OpenAI-zur-Herausgabe-von-Hugging-Face-Akten-11476501.html?wt_mc=rss.red.ho.themen.k%C3%BCnstliche+intelligenz.beitrag.beitrag
Why did we choose this article?
A state legal probe could force OpenAI to disclose internal incident documents — this affects transparency, regulatory oversight, and how companies may be required to report AI-related incidents.

Google restricts Gemini access for AI Plus customers.
Source: https://www.heise.de/news/Google-Gemini-Pro-Modelle-erfordern-ab-Oktober-ein-AI-Pro-Abo-11476479.html?wt_mc=rss.red.ho.themen.k%C3%BCnstliche+intelligenz.beitrag.beitrag
Why did we choose this article?
Google is moving access to its pro Gemini models behind a new paid 'AI Pro' tier, meaning existing AI-Plus users will lose features unless they upgrade — a direct change to what paying users can access and may affect subscription choices and costs.

OpenAI marks ChatGPT texts with an invisible watermark.
Source: https://the-decoder.de/openai-versieht-chatgpt-texte-mit-unsichtbarem-wasserzeichen/
Why did we choose this article?
OpenAI is adding an invisible watermark to ChatGPT outputs (initially in the EU), which changes how reliably AI-generated text can be detected — important for publishers, educators, and businesses checking provenance or enforcing policies.

This startup is issuing AI-generated acne prescriptions.
Source: https://www.theverge.com/ai-artificial-intelligence/1005075/nolla-health-acne-ai-prescriptions
Why did we choose this article?
An app that scans faces and autonomously issues prescriptions is now available to consumers in Utah — a concrete change to how people can access medical treatment, raising questions about safety, oversight, and convenience.

Do you have any questions, comments, or suggestions for improvement? We welcome your feedback at podcast@pickert.de.